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BACKGROUND: Limited information exists regarding procedural success and clinical outcomes in patients with previous coro-
nary artery bypass grafting (CABG) undergoing percutaneous coronary intervention (PCI). We sought to compare outcomes 
in patients undergoing PCI with or without CABG.
METHODS AND RESULTS: This was an observational cohort study of 123 780 consecutive PCI procedures from the Pan- London 
(UK) PCI registry from 2005 to 2015. The primary end point was all- cause mortality at a median follow- up of 3.0 years (in-
terquartile range, 1.2–4.6 years). A total of 12 641(10.2%) patients had a history of previous CABG, of whom 29.3% (n=3703) 
underwent PCI to native vessels and 70.7% (n=8938) to bypass grafts. There were significant differences in the demographic, 
clinical, and procedural characteristics of these groups. The risk of mortality during follow- up was significantly higher in 
patients with prior CABG (23.2%; P=0.0005) compared with patients with no prior CABG (12.1%) and was seen for patients 
who underwent either native vessel (20.1%) or bypass graft PCI (24.2%; P<0.0001). However, after adjustment for baseline 
characteristics, there was no significant difference in outcomes seen between the groups when PCI was performed in native 
vessels in patients with previous CABG (hazard ratio [HR],1.02; 95%CI, 0.77–1.34; P=0.89), but a significantly higher mortality 
was seen among patients with PCI to bypass grafts (HR,1.33; 95% CI, 1.03–1.71; P=0.026). This was seen after multivariate 
adjustment and propensity matching. 
CONCLUSIONS: Patients with prior CABG were older with greater comorbidities and more complex procedural characteristics, 
but after adjustment for these differences, the clinical outcomes were similar to the patients undergoing PCI without prior 
CABG. In these patients, native- vessel PCI was associated with better outcomes compared with the treatment of vein grafts.
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Patients with prior coronary artery bypass graft-ing (CABG) often require further revascularization as a result of recurrent symptoms of angina or presentation with an acute coronary syndrome (ACS). This occurs because of the progression of atheroscle-rotic disease both in the native coronary arteries and 
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particularly within saphenous vein grafts.1 It has previ-
ously been shown that up to 50% of vein grafts will have 
occluded or have a significant stenosis at 10 years.2,3 
Percutaneous coronary intervention (PCI) to saphe-
nous vein grafts, although a recognized treatment 
strategy, is associated with higher rates of restenosis 
as well as procedural complications and longer term 
major adverse cardiac events (MACEs).4–6 Despite this, 
in recent studies, vein grafts have remained the target 
vessel for PCI in at least 25% of cases.7,8
Limited information exists regarding procedural 
success and clinical outcomes in patients with previ-
ous CABG undergoing PCI. It is widely believed that 
technically feasible native coronary arteries should be 
the preferred target of  PCI in this patient group be-
cause native coronary artery PCI appears to be asso-
ciated with better short- term and long- term outcomes 
compared with bypass- graft PCI, as suggested in 
guidelines.9 However, there are limited data to sub-
stantiate this belief, and it is mainly based on consen-
sus opinion.7,8,10 
In the present study, we report outcomes from 
a large cohort of consecutive patients undergoing 
PCI. Limited studies have compared outcomes after 
PCI in patients with and without previous CABG 
and in the latter, outcomes after PCI in native ar-
teries against PCI to grafts. We therefore sought to 
describe the outcomes of PCI in patients with and 
without a history of prior CABG in a large unse-
lected cohort from the Pan- London Registry of the 
British Cardiovascular Intervention Society (BCIS). 
Outcomes were compared with the population with 
no history of prior CABG undergoing PCI during the 
same study period.
METHODS
The authors declare that all supporting data are avail-
able within the article.
This was an observational cohort study of 123 780 
consecutive PCI procedures from the Pan- London 
(United Kingdom) PCI registry. This is a prospectively 
collected data set that includes all patients treated 
by PCI in London, United Kingdom, during a study 
period of January 2005 to December 2015. This in-
cludes all patients undergoing PCIs performed for 
stable angina and ACS (ST- segment–elevation myo-
cardial infarction [STEMI], non–ST- segment–eleva-
tion myocardial infarction [NSTEMI], and unstable 
angina).
Pan- London PCI Registry
The UK BCIS audit collects data from all hospitals 
in the United Kingdom that perform PCI, record-
ing information about every procedure performed.11 
The database is part of the suite of data sets col-
lected under the auspices of the National Institute for 
Cardiovascular Outcomes Research and is compliant 
with UK data protection legislation. The Pan- London 
(United Kingdom) PCI registry includes all patients 
treated by PCI in the 9 PCI centers within the London, 
United Kingdom, area, which covers a population of 
8.2 million. The 9 tertiary cardiac centers in London 
are Barts Heart Centre (Barts Health National Health 
Service [NHS] Trust), St Georges Hospital (St Georges 
Healthcare NHS Foundation Trust), Kings College 
Hospital (King’s College Hospital NHS Foundation 
Trust), Royal Brompton and Harefield Hospitals 
(Royal Brompton & Harefield NHS Foundation Trust), 
CLINICAL PERSPECTIVE
What Is New?
• As a result of disease progression, patients with 
prior coronary artery bypass grafting often re-
quire further revascularization because of recur-
rent symptoms of angina or presentation with 
acute coronary syndromes.
• Limited information exists regarding procedural 
success and clinical outcomes in patients with 
previous coronary artery bypass grafting under-
going percutaneous coronary intervention.
What Are the Clinical Implications?
• This large observational study has shown that 
in patients with previous coronary artery bypass 
grafting, native-vessel percutaneous coronary 
intervention was associated with better out-
comes compared with the percutaneous coro-
nary intervention in vein grafts.
Nonstandard Abbreviations and Acronyms
ACS  acute coronary syndrome
BCIS   British Cardiovascular Intervention Society
CABG  coronary artery bypass grafting
LR  Log Rank
MACE  major adverse cardiac event
MI  myocardial infarction
NHS  National Health Service
NCDR  National Cardiovascular Data Registry
NSTEMI  non–ST-segment–elevation myocardial 
infarction
PCI  percutaneous coronary intervention
STEMI   non–ST-segment–elevation myocardial 
infarction
TIMI  thrombolysis in myocardial infarction
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Hammersmith Hospital (Imperial College Healthcare 
NHS Foundation Trust), Guys & St. Thomas’ Hospital 
(St Thomas’ NHS Foundation Trust), Royal Free 
Hospital (Royal Free NHS Foundation Trust) and the 
Heart Hospital (University College London Hospitals 
NHS Foundation Trust). The registry included 123 780 
patients who underwent PCI between 2005 and 
2015. We merged the anonymized databases of the 9 
London centers that collect data based on the BCIS 
data set. The BCIS audit is part of a national manda-
tory audit in which all UK PCI centers participate. PCI 
is defined as the use of any coronary device to ap-
proach, probe, or cross 1 or more coronary lesions 
with the intention of performing a coronary interven-
tion.11 Data are collected prospectively at each hos-
pital, electronically encrypted, and transferred online 
to a central database. Every patient entry offers de-
tails of the patient journey, including the method and 
timing of admission, inpatient investigations, results, 
treatment, and outcomes. Patients’ survival data are 
obtained by the linkage of patients’ NHS numbers to 
the Office of National Statistics, which records live/
death status and the date of death for all deceased 
patients. Patient and procedural details were re-
corded at the time of the procedure and during the 
admission into each center’s local BCIS database. 
Anonymous data sets with linked mortality data from 
the Office of National Statistics were merged for anal-
ysis from the 9 centers. 
Study Population and Procedures
Patient demographic characteristics were collected, 
including age, smoking status, left ventricular func-
tion, previous myocardial infarction (MI), previous re-
vascularization (PCI and CABG), indications for PCI, 
and New York Heart Association classification as well 
as the presence of hypertension, diabetes mellitus, 
cardiogenic shock, hypercholesterolemia, peripheral 
vascular disease, preprocedural cardiac arrest and 
chronic kidney disease (defined as creatinine>200 or 
renal replacement therapy). The technical aspects of 
the PCI procedure were also recorded as well as ad-
verse outcomes, including complications up to the time 
of hospital discharge. Patients undergoing PCI were 
loaded with antiplatelet drugs prior to their procedures 
(clopidogrel [300–600 mg] and aspirin [300 mg]). The 
clopidogrel was typically continued for 1 month post-
implantation of a bare- metal stent or 1  year if drug- 
eluting stent implantation occurred or if the procedure 
was performed for an MI. The use of adjunctive phar-
macology (glycoprotein IIb/IIIa inhibitors, bivalirudin, 
heparin, and thrombolysis) was left to the discretion 
of the interventional cardiologist performing the pro-
cedure. Coronary artery disease was classified by se-
verity of luminal narrowing (0%, 1%–49%, 50%–74%, 
75%–94%, 95%–99%, or 100%) and by vessel ef-
fected (eg, left anterior descending). 
Clinical Outcomes
The primary clinical outcome was all- cause mortal-
ity, with data obtained from the UK Office for National 
Statistics. Secondary outcomes were in- hospital 
MACE defined as a composite of all- cause mortal-
ity, PCI- related MI (new ischemic pain with new ST 
elevation and elevation of enzymes whether treated 
with further revascularization therapy), stroke and re-
intervention PCI. Non- MACE complications included 
arterial complications, aortic dissection, coronary 
dissection (dissection defined as unintentional intimal 
disruption using the National Heart, Lung, and Blood 
Institute classification system for intimal tears12 and 
coronary perforation). We hypothesized that adverse 
clinical outcomes in patients with previous CABG are 
driven by baseline comorbidities and the treatment 
of VGs (vein grafts) rather than native coronary artery 
disease. Therefore, we also hypothesized that the out-
come of native- vessel PCI in previous CABG is no dif-
ferent from patients without prior CABG. 
Ethics
The data collected were part of a mandatory national 
cardiac audit, and all patient- identifiable fields were re-
moved prior to merging the data sets and analysis. The 
local ethics committee advised that formal ethical ap-
proval was not required for this study.
Statistical Analysis
For the purposes of statistical analysis, the study 
population was divided into the following 3 groups: 
(1) no previous CABG, (2) prior CABG with PCI to na-
tive coronary arteries, and (3) prior CABG with PCI to 
bypass grafts. The characteristics of patients were 
compared across the 3 groups. These comparisons 
were performed using Fisher’s exact tests for binary/
categorical variables and ANOVA for continuous vari-
ables. Normality of distribution was assessed using 
the Shapiro- Wilks test. We calculated Kaplan- Meier 
product limits for cumulative probability of reaching an 
end point and used the log- rank test for evidence of a 
statistically significant difference between the groups. 
In the case of missing data (except for left ventricular 
ejection fraction), unknown values were imputed to the 
most common categorical variable and to the median 
or subgroup- specific median of continuous variables. 
Time was measured from the index admission to out-
come (all- cause mortality). 
Cox regression analysis was used to estimate 
hazard ratios for the effect of previous CABG in 
age- adjusted and fully adjusted models based on 
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covariates (P<0.05) associated with the outcome. 
A number of covariates were included in the model, 
including age, sex, diabetes mellitus, hypertension, 
hypercholesterolaemia, previous PCI, previous MI, 
chronic renal failure, preprocedure thrombolysis in 
MI (TIMI) flow, year of study, procedural success, left 
main stem intervention, and glycoprotein IIb/IIIA use. 
The proportional hazards assumption was evaluated 
by examining log (- log) survival curves and addition-
ally was tested with Schoenfield’s residuals. The 
proportional hazard assumption was satisfied for all 
outcomes evaluated. In addition, a sensitivity analy-
sis was performed to evaluate the effect of including 
or excluding ejection fraction or previous PCI to the 
multivariate model. Normality was confirmed for all 
variables, and therefore we conducted ANOVA for all 
analyses.
A propensity score analysis was carried out using 
a nonparsimonious logistic regression model com-
paring previous CABG and no CABG and previous 
bypass- graft versus native- vessel intervention. Multiple 
variables were included in the model, including age, 
sex, diabetes mellitus, hypertension, hypercholestero-
laemia, previous PCI, previous MI, chronic renal fail-
ure, preprocedure TIMI flow, procedural success, left 
main stem intervention, and glycoprotein IIb/IIIA use. 
After ranking propensity score in an ascending order, 
a nearest- neighbor 1:1 matching algorithm was used 
with callipers of 0.2 standard deviations of the logit of 
the propensity score. Each CABG and no CABG and 
previous bypass- graft versus native- vessel interven-
tion was used in at most 1 matched pair to create a 
matched sample with a similar distribution of baseline 
characteristics between the observed groups. Based 
on the matched samples, the Cox proportional haz-
ard model was used to determine the association of 
complete revascularization on mortality over follow- up. 
Statistical analyses were performed using Stata ver-
sion 14 (Stata Corp, College Station, TX). 
RESULTS
There were 123 780 PCI procedures performed dur-
ing the study period. The patient demographics and 
risk factor profiles were as expected for an unselected 
PCI registry (Table  1). Patients had a mean age of 
64.3±12.1 years and 25.2% were women; 22.4% of the 
patients were diabetic, and 27.3% had a history of pre-
vious MI.
A total of 12 641 (10.2%) of the patients had a his-
tory of prior CABG, and 111 139 of the patients had 
no prior history of CABG (268 patients with previous 
CABG who underwent treatment of graft and na-
tive vessel were excluded). In patients with previous 
CABG, 3703 (29.3%) underwent the treatment of a 
native coronary artery compared with 8938 (70.7%) 
who underwent bypass- graft treatment. The propor-
tion of PCIs performed in patients with previous CABG 
Table 1. Baseline Characteristics Split Into Patients With and Without Previous CABG   
PCI to Native, No CABG 
(n=111 139)
PCI to Native in CABG 
(n=3703)
PCI to Grafts 
(n=8938) P Value
Age, y 63.72±12.39 69.83±9.41 67.76±10.17 <0.0001
Ethnicity, white 4845 (43.5) 1352 (36.5) 4183 (46.8) <0.0001
Sex, male 82 576 (74.3) 3025 (81.7) 2472 (87.1) <0.0001
Previous MI 29 785 (26.8) 2414 (65.2) 5202 (58.2) <0.0001
Previous PCI 26 896 (24.2) 1689 (45.6) 4308 (48.2) <0.0001
Hypercholesterolaemia 78 353 (70.5) 2588 (69.9) 6355 (71.1) 0.108
Diabetes mellitus 24 895 (22.4) 1359 (36.7) 3155 (35.3) <0.0001
Hypertension 60 904 (54.8) 2540 (68.6) 6114 (68.4) <0.0001
Smoking history 66 572 (59.9) 2244 (60.6) 6239 (59.8) 0.084
PVD 3112 (2.8) 185 (5.0) 572 (6.4) <0.0001
CKD (creatinine>200) 445 (4.0) 259 (7.0) 742 (8.3) <0.0001
Previous CVA 111 (0.1) 4 (0.1) 18 (0.2) 0.220
Poor LV function 8447 (7.6) 430 (11.6) 920 (10.3) <0.0001
Presentation
STEMI 29 785(26.8) 378 (10.2) 1282 (14.3) <0.0001
NSTEMI 33 897 (30.5) 1141 (30.8) 3048 (34.1) <0.0001
Elective 47 456 (42.7) 2185 (59.0) 4612 (51.6) <0.0001
Cardiogenic shock 3112 (2.8) 67 (1.8) 143 (1.6) <0.0001
Data are mean±SD or number (percentage). CABG indicates coronary artery bypass grafting; CKD, chronic kidney disease; CVA, cerebrovascular accident; 
LV, left ventricular; MI, myocardial infarction; MV, multivessel; NSTEMI, non–ST- segment–elevation myocardial infarction; PCI, percutaneous coronary 
intervention; PVD, peripheral vascular disease; and STEMI, ST- segment–elevation myocardial infarction.
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increased over time (10.5%–15.3%). During the study 
period, there was a reduction in the treatment of by-
pass grafts: 6.6% in 2006 to 5.7% in 2015 (P=0.03) 
compared with native PCI, which increased over time 
(4.2%–6.1%).
Baseline and Procedural Characteristics
The patient characteristics are summarized in Table 1. 
There were significant differences in the demographic, 
clinical, and procedural characteristics of the 3 groups. 
Patients with previous CABG were significantly older 
and had a higher prevalence of diabetes mellitus, 
hypertension, peripheral vascular disease cerebro-
vascular disease, and previous MI/percutaneous re-
vascularization (PCI).
Patients without previous CABG were more likely 
to undergo the procedure via the radial route followed 
by native- vessel treatment in previous CABG, with 
the lowest radial access rates seen in vein- graft PCI. 
Higher rates of chronic total occlusion intervention, 
intravascular ultrasound, and drug- eluting stent use 
were seen in native versus graft PCI (Table 2). On mul-
tivariable analysis, lower baseline TIMI flow grade, ACS 
presentation, male sex, renal failure, diabetes mellitus, 
and the presence of a chronic total occlusion were as-
sociated with a higher likelihood of graft versus native 
coronary artery PCI. The rates of chronic total occlu-
sion intervention varied across patient presentations 
and were reported as being the treated vessel in 38.1% 
of elective cases, 19.3% in NSTEMI cases, and 4.6% in 
STEMI cases; consequently, the rates of VG PCI also 
varied across treatment groups with opposite trends 
(3.2% versus 25.8% versus 39.7%).
Clinical Outcomes
In- Hospital Outcomes
Procedural and vascular complication rates were gen-
erally low but were higher in patients undergoing vein- 
graft PCI compared with the other groups, particularly 
rates of no reflow (P=0.002). However, bleeding com-
plications were similar across all 3 groups: 0.7% (no 
CABG) versus 0.6% (native vessel) versus 0.7% (graft 
PCI). In- hospital event rates were similar across all 3 
groups: 4.0% (no CABG) versus 4.3% (native vessel) 
versus 3.7% (graft PCI) for MACE, and 1.5% versus 
1.3% versus 1.6%, respectively, for mortality.
All- Cause Mortality
Previous CABG
A significant unadjusted difference in mortality was 
observed between patients with no history of prior 
CABG (12.1%) compared with patients with prior 
CABG (23.2%) (P=0.0005) and was seen for patients 
who underwent either native- vessel (20.1%) or bypass- 
graft PCI (24.2%; P<0.0001; Figure 1). Higher rates of 
mortality were seen dependent on PCI indication, with 
higher rates in ACS compared with stable in patients 
with prior CABG (P<0.0001; Figure 2A).
Table 2. Procedural Characteristics Split Into Patients With and Without Previous CABG
PCI to Native, No CABG 
(n=111 139)
PCI to Native in CABG 
(n=3703) PCI to Grafts (n=8938) P Value
Access for PCI
Radial 36 898 (33.2) 781 (21.1) 903 (10.1) <0.0001
Vessel treated <0.0001
Left main 2890 (2.6) 1126 (30.4) 0 (0)
LAD 58 015 (52.2) 3355 (90.6) 0 (0)
Left circumflex 27 340 (24.6) 1259 (34.0) 0 (0)
RCA 42 455 (38.3) 1074 (29.0) 0 (0)
Grafts 0 (0) 0 (0) 8938 (100)
CTOs 9336 (12.4) 1056 (28.6) 0 (0) <0.0001
Multivessel PCI 23 673 (21.3) 618 (16.7) 1207 (13.5) 0.018
Mean stent number 1.55±1.15 1.53±1.20 1.55±1.13 0.012
Lesion diameter, mm 3.18±2.10 3.20±2.78 3.94±3.58 <0.0001
Lesion length, mm 22.68±13.80 22.91±15.59 21.73±11.81 0.182
Distal protection device 222 (0.2) 41 (1.1) 1394 (15.6) <0.0001
IVUS use 5001(4.5) 178 (4.8) 268 (3.0) <0.0001
DES use 101 692 (91.5) 3485 (94.1) 7588 (84.9) <0.0001
GP IIb/IIIa inhibitor 27 118 (24.4) 1215 (32.8) 4219 (47.2) <0.0001
Procedural success 102 470 (92.2) 3403 (91.9) 8017 (89.7) 0.002
Data are mean±SD or number (percentage). CABG indicates coronary artery bypass grafting; CTO, chronic total occlusion; DES, drug- eluting stent; GP IIb/
IIIa, glycoprotein IIb/IIIa; IVUS, intravascular ultrasound; LAD, left anterior descending; PCI, percutaneous coronary intervention; and RCA, right coronary artery.
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In the unadjusted univariate analysis, the risk of mortal-
ity during follow- up was significantly higher in patients 
with previous CABG (hazard ratio [HR], 2.11; 95% CI, 
1.40–2.97; P=0.007) compared with patients without 
CABG. However, after adjustments for baseline co-
variates, there was no association between previous 
CABG and outcome (HR, 1.26; 95% CI, 0.85–1.74; 
P=0.59; Table  3). Variables showing an independent 
association with mortality were age, cardiogenic 
shock, chronic renal failure, and severe systolic left 
ventricular impairment. Radial artery access and pro-
cedural success were also independently associated 
with survival.
Native Versus Graft PCI
In the unadjusted univariate analysis, the risk of mor-
tality during follow- up was significantly higher in pa-
tients undergoing PCI to a bypass graft (HR, 1.38; 
Figure 1. Kaplan- Meier curves showing cumulative probability of all- cause mortality after PCI 
according to group: (A) PCI in patients who have had CABG vs no CABG and (B) PCI to native vs 
grafts.
CABG indicates coronary artery bypass grafting; LR, Log Rank; and PCI, percutaneous coronary 
intervention.   
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95% CI, 1.08–1.81; P=0.003) and PCI undertaken 
in native coronary arteries in patients with previ-
ous CABG (HR, 1.19; 95% CI, 1.10–1.67; P=0.007) 
compared with PCI in native coronary arteries. 
Interestingly, when assessing by indication for PCI, 
no difference between PCI to a native vessel and PCI 
to a VG was seen in patients presenting with ACS; 
however, significant differences exist between the 2 
groups in stable coronary artery disease (P<0.0001; 
Figure 2B).
After adjustments for baseline covariates, there was 
no significant difference in outcomes for PCI in na-
tive vessels in patients with CABG (HR, 1.02; 95% CI, 
0.77–1.34; P=0.89), but a significantly higher mortality 
among patients with PCI to bypass grafts (HR, 1.33; 
95% CI, 1.03–1.71; P=0.026; Table 4). The aforemen-
tioned Cox proportional hazard model was repeated 
with the year of procedure included as a categorical 
variable to allow for improvements in PCI technique 
and technology during the long study period. This 
confirmed the associations between bypass- graft PCI 
(HR, 1.42; 95% CI, 1.08–1.83; P=0.0004) and mortal-
ity, with no difference seen between the native- vessel 
PCI in previous CABG and native- vessel treatment 
with no previous bypass (HR, 1.05; 95% CI, 0.62–1.26; 
P=0.45). 
Figure 2. Kaplan- Meier curves showing cumulative probability of all- cause mortality after PCI 
according to presentation: (A) PCI in patients who have had coronary artery bypass grafting 
(acute coronary syndrome vs stable) and (B) PCI to native vs grafts in acute coronary syndrome 
vs stable. 
ACS indicates acute coronary syndrome; LR, Log Rank; and PCI, percutaneous coronary intervention.
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Clinical Outcomes in the Propensity- 
Matched Populations
Two propensity- matched cohorts were assessed: 
prior CABG versus no prior CABG (24 200 patients, 
12 100 patients in each group) and bypass- graft ver-
sus native- vessel PCI in patients with previous bypass 
(7302 patients, 3651 in each group). The baseline de-
mographics and procedural variables were well bal-
anced in each of the propensity- matched cohorts, 
with the minimal P value after matching comparing 
the variables between the 2 groups being P>0.40 in 
all matched groups.
All- Cause Mortality
No differences in outcomes between patients with or 
without previous CABG were seen after propensity 
matching in the unadjusted and adjusted analyses. 
However, when comparing patients with previous 
CABG where PCI was performed in either the na-
tive vessel or the graft, a significant association with 
Table 3. Cox Proportional Model of Univariate and Multivariate Analysis of Predictors of Mortality in the Whole Population 
Variable Comparator Univariate Multivariable
Age Age 1.08 (1.07–1.08) 1.07 (1.06–1.08)
Male Female 1.30 (1.26–1.35) 1.03 (0.94–1.13)
Ethnicity (Asian) White 1.18 (1.15–1.22) 1.07 (0.97–1.17)
Cardiogenic shock No cardiogenic shock 4.64 (4.33–4.98) 3.77 (3.25–4.36)
Diabetic Nondiabetic 1.53 (1.47–1.59) 1.47 (1.34–1.62)
Previous MI No previous MI 1.49 (1.44–1.55) 1.26 (1.14–1.40)
Previous PCI No previous PCI 1.06 (1.07–1.15) 1.02 (0.91–1.14)
Hypertension No hypertension 1.40 (1.35–1.45) 1.03 (0.94–1.13)
Hypercholesterolaemia No hypercholesterolaemia 1.01 (0.98–1.05) 1.01 (0.95–1.08)
eGFR<60 mL/min per 1.73 m2 eGFR>60 4.22 (4.00–4.46) 2.44 (2.10–2.84)
EF<35% EF>35% 2.18 (2.04–2.33) 1.75 (1.54–1.98)
GP IIb/IIIa inhibitor use No GP IIb/IIIa inhibitor use 0.91 (0.87–0.94) 0.94 (0.83–1.26)
Procedural success Procedural failure 0.63 (0.58–0.67) 0.72 (0.62–0.82)
Access route (radial) Femoral 0.88 (0.84–0.92) 0.93 (0.87–0.96)
Previous CABG No previous CABG 2.67 (1.40–2.97) 1.26 (0.85–1.74)
The overall sample size included 98.5% of the patients in this analysis. CABG indicates coronary artery bypass grafting; EF, ejection fraction; eGFR, estimated 
glomerular filtration rate; GP IIb/IIIa, glycoprotein IIb/IIIa; MI, myocardial infarction; and PCI, percutaneous coronary intervention.
Table 4. Cox Proportional Model of Univariate and Multivariate Analysis of Predictors of Mortality in Patients With 
Previous CABG
Variable Comparator Univariate Multivariable
Age Age 1.06 (1.06–1.07) 1.05 (1.04–1.06)
Male Female 1.18 (1.06–1.32) 1.05 (0.87–1.28)
Ethnicity (Asian) White 1.19 (1.09–1.30) 1.33 (1.14–1.55)
Cardiogenic shock No cardiogenic shock 5.56 (4.40–7.04) 4.31 (2.91–6.37)
Diabetic Nondiabetic 1.28 (1.17–1.40) 1.36 (1.17–1.58)
Previous MI No previous MI 1.45 (1.32–1.60) 1.30 (1.10–1.52)
Previous PCI No previous PCI 1.03 (0.94–1.12) 1.05 (0.92–1.16)
Hypertension No hypertension 1.16 (1.05–1.28) 1.03 (0.87–1.23)
Hypercholesterolaemia No hypercholesterolaemia 1.14 (1.03–1.26) 1.26 (1.06–1.49)
eGFR<60 mL/min per 1.73 m2 eGFR>60 3.19 (2.81–3.62) 2.12 (1.70–2.65)
EF<35% EF>35% 2.19 (1.87–2.57) 1.74 (1.43–2.11)
GP IIb/IIIa inhibitor use No GP IIb/IIIa inhibitor use 0.94 (0.80–1.04) 0.96 (0.83–1.26)
Procedural success Procedural failure 0.83 (0.67–1.03) 0.76 (0.60–0.89)
Access route (radial) Femoral 0.97 (0.87–1.13) 0.93 (0.87–0.99)
Bypass- graft intervention Native- vessel intervention 1.38, 95% (1.08–1.81) 1.33 (1.03–1.71)
The overall sample size included 97.3% of the patients in this analysis. CABG indicates coronary artery bypass grafting; EF, ejection fraction; eGFR, estimated 
glomerular filtration rate; GP IIb/IIIa, glycoprotein IIb/IIIa; MI, myocardial infarction; and PCI, percutaneous coronary intervention.
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mortality was seen with graft PCI (13.6% versus 
23.8%; P<0.0001). When applying Cox multivariate 
regression analysis to adjust for baseline clinical and 
procedural characteristics, native- vessel PCI was 
an independent predictor for reduced mortality (HR, 
0.69; 95% CI, 0.21–0.87; P=0.0008) compared with 
graft PCI, but not when compared with native- vessel 
PCI (no prior CABG; HR, 1.08; 95% CI, 0.51–1.48; 
P=0.53).
DISCUSSION
The results in this study encompass outcomes for 
one of the largest groups of consecutive patients 
with and without prior CABG undergoing PCI for 
stable coronary syndromes and ACSs, specifically 
comparing the outcomes of patients with and with-
out CABG and treatment to both native coronary 
arteries and bypass grafts. We have shown that sig-
nificantly higher mortality rates are associated with 
prior CABG, but these are corrected for by an adjust-
ment for comorbidities. Interestingly, among patients 
with previous CABG who underwent PCI to a bypass 
graft, higher mortality rates were seen compared with 
if a native vessel was treated, whereas no difference 
was seen with native- vessel treatment when com-
pared with patients without prior CABG. This adds 
further evidence to support the concept that a native 
vessel should be treated if possible when performing 
secondary revascularization in this group of patients 
postsurgery.13 It is also worth emphasizing that al-
though in- hospital event rates, including death, were 
comparable across all 3 study groups, the patients 
who had PCI to a bypass graft had significantly ele-
vated mortality after discharge over time, even when 
the baseline characteristics had been corrected for. 
The reassurance of a technically successful PCI to a 
bypass graft is not necessarily a strong predictor of 
good long- term outcome.
Although there are data to support that PCI in 
these patients should be performed to native ves-
sels where possible,13 >70% of patients in our data 
set with prior CABG underwent PCI to a bypass 
graft. Although in keeping with other analyses from 
the United Kingdom,10 albeit a primary PCI cohort, 
this is a much higher proportion of patients than 
seen in other similar studies. A series of studies from 
the United States has shown rates of bypass- graft 
intervention of around 43% both in 200214 and more 
recently in 2009. The largest study by Brilakis et al8 
looked at 300  902 patients with prior CABG from 
the NCDR (National Cardiovascular Data Registry) 
CathPCI Registry demonstrated the target vessel 
for PCI was a bypass graft in only 37.5% of their 
patients. This may reflect the fact that 43% of their 
study cohort were >10 years post CABG at the time 
of PCI, which is known to influence decision mak-
ing; however, further study is needed to understand 
these differences. It is likely that anatomy rather than 
clinician choice may drive this decision, and whether 
native options were available when a bypass graft 
was treated is unknown and warrants further study. 
The type of presentation appears to have an impact 
on the target lesion. In our study, patients presenting 
with STEMI after prior CABG accounted for a greater 
proportion of bypass- graft PCI than native- vessel PCI 
(15.2% versus 9.6%; P<0.0001), whereas patients pre-
senting with stable symptoms after prior CABG ac-
counted for 61% of PCI to native vessels versus 46% 
of PCI to bypass grafts (P<0.0001). This is similar to 
other studies that have identified that patients with 
prior CABG who received PCI to a native vessel were 
more likely to present with stable angina rather than an 
ACS.14,15Other factors aside from clinical presentation 
that were associated with a higher likelihood of graft 
PCI in our study included male sex, renal failure, diabe-
tes mellitus, and lower baseline TIMI flow grade. These 
are similar factors as those described by Brilakis et al.8 
They also reported that saphenous vein- graft PCI con-
stituted an increasing proportion of PCI as time from 
CABG lengthened, reflecting the difficulties in treat-
ment of progressive native coronary artery athero-
sclerosis. Our study demonstrated that the proportion 
of PCIs performed on bypass grafts relative to native 
vessels decreased over time despite the likelihood of 
greater anatomical complexity. This may reflect the 
advancing techniques in the treatment of native- vessel 
chronic total occlusions with higher rates seen in this 
cohort than other published series. 
Consistent with previous studies, we have shown 
that in- hospital MACE rates and all- cause mortality 
were higher in patients with previous CABG under-
going PCI to a bypass graft. Brilakis et al8 reported a 
higher in- hospital mortality after bypass- graft interven-
tion when compared with native coronary intervention. 
In 2010, the APEX- AMI (Assessment of Pexelizumab 
in Acute Myocardial Infarction) trial looked at 5745 pa-
tients presenting with STEMI, including 128 patients 
with prior CABG. They reported that TIMI III flow was 
achieved less often on treatment of a bypass- graft cul-
prit lesion, and they found that the 90- day mortality 
in these patients was higher compared with patients 
with prior CABG treated for a native culprit lesion (19% 
versus 5.7%).16  Further supportive data are provided 
by a small observational study by Mavroudis et al17 that 
looked at graft versus native- vessel PCI and found that 
VG PCI had worse outcomes compared with native 
coronary PCI, with high rates of mortality, restenosis, 
and occlusion. They found that graft- vessel PCI had 
5 times higher rates of target- vessel revascularization 
compared with those undergoing native- vessel treat-
ment, supporting the data provided our larger data set, 
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although greater anatomical information and outcomes 
such as target vessel revascularisation were available. 
To date there are limited data supporting native ver-
sus graft intervention in this patient cohort with no ran-
domized trial data performed. In 2000, Mathew et al18 
published data on patients with and without previous 
CABG undergoing PCI for unstable angina showing 
that although treatment of a native coronary lesion 
compared with a bypass graft reduced the likelihood 
of death, MI, and/or repeat revascularization, previ-
ous CABG was still associated with a higher risk when 
compared with non- CABG patients undergoing PCI. 
Other studies such as that from the Mayo clinic, of 1072 
patients undergoing primary PCI of which 128 had a 
history of prior CABG, showed that during 1 year of fol-
low- up, previous CABG was associated with adverse 
cardiac events, but not after adjustment for baseline 
characteristics, where only vein- graft treatment was in-
dependently associated with adverse cardiac events, 
whereas previous CABG was not.19 The APEX- AMI 
trial further added to this evidence by finding no dif-
ference in outcome between patients with prior CABG 
treated for a native culprit vessel compared with pa-
tients without a history of bypass. Our study has gone 
on to confirm these data in a large population of pa-
tients treated both electively and acutely with the lon-
gest follow- up reported to date. This provides a strong 
rationale to support further randomized study in this 
increasingly seen patient cohort specifically the ongo-
ing PROCTOR (Percutaneous Coronary Intervention of 
Native Coronary Artery Versus Venous Bypass Graft in 
Patients With Prior CABG) trial (https://clini caltr ials.gov/
ct2/show/NCT03 805048), which is investigating this 
exact question. 
The Pan- London BCIS data set includes the com-
plete collection of all PCI procedures performed in 
London, United Kingdom, representing unselected 
real- world experience, including high- risk patients 
often excluded from randomized controlled trials. We 
recognize that this study has several potential limita-
tions. First, this was an observational study associated 
with the inherent biases of the study design; however, 
differences in baseline and clinical characteristics were 
adjusted in a multivariate analysis, and a propensity 
analysis was performed to further account for con-
founding. We report all- cause mortality and although 
mortality tracking within the United Kingdom is robust, 
all other outcomes and complications are self- reported 
without formal adjudication. Therefore, the analysis is 
potentially vulnerable to reporting biases, and com-
plications may be underreported. In addition, we did 
not provide information about target lesion–related 
end points (ie, target- vessel MI or revascularization) 
that would enable us to accurately assess the prog-
nostic implication of native- vessel versus vein- graft 
intervention. Hence, we cannot differentiate whether 
the outcomes were mediated by differences in MI 
or requirements for repeat revascularization, and we 
also unfortunately can only report all- cause and not 
cardiac- specific mortality. Finally, our analyses report 
outcomes derived from grafts because the BCIS data 
set does not differentiate between venous and arterial 
grafts. Previous data derived from the NCDR CathPCI 
registry suggest that arterial grafts represented 2.5% 
of all PCI procedures undertaken to bypass grafts in 
the United States, although this did not report practice 
or outcomes in a primary PCI cohort specifically.8
CONCLUSIONS
Patients with prior CABG treated with PCI had greater 
comorbidities, but once these differences were ad-
justed for, prior CABG was not associated with mor-
tality. Native- vessel PCI was associated with improved 
outcomes compared with the treatment of vein grafts 
and prior to further study, native coronary arteries 
should be considered if amenable to PCI, as the target 
vessel of choice, over PCI to bypass grafts.” 
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